Synergy of karenitecin and mafosfamide in pediatric leukemia, medulloblastoma, and neuroblastoma cell lines

Pediatric Blood and Cancer

Volumn 50, Issue 4, 2008, Pages 757-760

  Jacob, Eufemia ^a,c   Scorsone, Kathy ^a   Blaney, Susan M ^a   D'Argenio, David Z ^b   Berg, Stacey L ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b University of Southern California ^*  (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Intrathecal therapy; Karenitecin; Mafosfamide; Synergy

Indexed keywords

KARENITECIN; MAFOSFAMIDE; TETRAZOLIUM;

ARTICLE; CANCER CELL CULTURE; CELL ASSAY; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG POTENTIATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; LEUKEMIA; MEDULLOBLASTOMA; NEUROBLASTOMA; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CELL LINE, TUMOR; CHILD; CYCLOPHOSPHAMIDE; DRUG SYNERGISM; HUMANS; LEUKEMIA; MEDULLOBLASTOMA; NEUROBLASTOMA;

EID: 40449086026     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21330     Document Type: Article

References (25)

1. Blaney S, Poplack D. New cytotoxic drugs for intrathecal administration. J Neurooncol 1998;38:219-223.
2. Kerr J, Berg S, Blaney S. Intrathecal chemotherapy. Crit Rev Oncol Hematol 2001;37:227-236.
3. Hausheer F, Cao S, Kanter P, et al. Karenitecins: new preclinical developments with BNP1350; a novel, potent highly lipophilic camptothecin. AACR Abstr 1999; 741.
4. Hausheer F, Haridas K, Zhao M, et al. Karenitecins: A novel class of orally active highly lipophilic topoisomerase I inhibitors. Proc Am Assoc Cancer Res 1997;39:420.
5. Hausheer F, Kanter P, Cao S, et al. Modulation of platinum-induced toxicities and therapeutic index: Mechanistic insights and first- and second-generation protecting agents. Semin Oncol 1998;25:584-599.
6. Kerr J, Berg S, Hausheer F, et al. Karenitecins: Cytotoxicity studies in pediatric tumor cell lines. Proc Am Assoc Cancer Res 1999;40:112.
7. Alberts D, Einspahr J, Struck R, et al. Comparative in vitro cytotoxicity of cyclophosphamide, its major active metabolites and the new oxazaphosphorine ASTA Z 7557 (INN mafosfamide). Invest New Drugs 1984;2:141-148.
8. Mosmann T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63.
9. Twentyman P, Luscombe M. A study of some variables in a tetrazolium dye (MTT) based assay for cell growth and chemosensitivity. Br J Cancer 1987;56:279-285.
10. Greco W, Park H, Rustrum Y. Application of a new approach for the quantitation of drug synergism to the combination of cis- diamminedichloroplatinum and 1-B-D-arabinofuranosylcytosine. Cancer Res 1990;50:5318-5327.
11. D'Argenio D, Schumitzky A. ADAPT II User's Guide: Pharmacokinetic/ Pharmacodynamic Systems Analysis Software Los Angeles: Biomedical Simulations Resource, 1997.
12. Horton TM, Gannavarapu A, Blaney SM, et al. Bortezomib interactions with chemotherapy agents in acute leukemia in vitro. Cancer Chemother Pharmacol 2006;58:13-23. Epub 2005 Nov 15.
13. Berenbaum MC. What is synergy? Pharmacol Rev 1989;41:93-141.
14. Chou T, Talalay P. Quantitative analysis of dose-effect relationship: The combined effect of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27.
15. Greco WR, Bravo G, Parsons JC. The search for synergy: A critical review from a response surface perspective. Pharmacol Rev 1995;47:331-385.
16. Cheng M, Chatterjee S, Berger N. Schedule dependent cytotoxicity of topotecan alone and in combination regimens. Oncol Res 1994;6:269-279.
17. Ma J, Maliepaard M, Nooter K, et al. Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a panel of eight solid-tumor cell lines in vitro. Cancer Chemother Pharmacol 1998;41:307-316.
18. Masumoto N, Nakano S, Esaki T, et al. Sequence-dependent modulation of anticancer drug activities by 7-ethyl-10-hydroxycamptothecin in an HST-1 human squamous carcinoma cell line. Anticancer Res 1995;15:405.
19. Romanelli S, Perego P, Pratesi G, et al. In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems. Cancer Chemother Pharmacol 1998;41:385-390.
20. Rowinsky E, Kaufmann S, Baker S, et al. Sequences of topotecan and cisplatin: Phase I, pharmacologic and in vitro studies to examine sequence dependence. J Clin Oncol 1996;40:3074.
21. Slavc I, Schuller E, Czech T, et al. Intrathecal mafosfamide therapy for pediatric brain tumors with meningeal dissemination. J Neurooncol 1998;38:213-218.
22. Slavc I, Schuller E, Falger J, et al. Feasibility of long-term intraventricular therapy with mafosfamide (n = 26) and etoposide (n = 11): Experience in 26 children with disseminated malignant brain tumors. J Neurooncol 2003;64:239-247.
23. Blaney S, Phillips P, Packer R, et al. Phase II evaluation of topotecan for pediatric central nervous system tumors. Cancer (Phila.) 1996;78:527-531.
24. Blaney S, Heideman R, Berg S, et al. Phase I Clinical Trial of Intrathecal Topotecan in Patients with Neoplastic Meningitis. J Clin Oncol 2003;21:143-147.
25. Blaney SM, Balis FM, Berg S, et al. Intrathecal mafosfamide: A preclinical pharmacology and phase I trial. J Clin Oncol 2005;23:1555-1563.